Novartis granted OK to market Gleevec in children with Ph+ ALL
This article was originally published in Scrip
Executive Summary
Novartis received approval from the US FDA to again expand the use of Gleevec (imatinib), this time in combination with chemotherapy to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).